The approval could speed access to twice-yearly generic lenacapavir in 120 low- and middle-income countries, at an expected cost of $40 a year per person.
Reported by 2 outlets
This Week in Medicine
The week in medicine, in five minutes
The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.